Patient P-01512
Therapy response
Improving
Tolerance
Improving
GI state
Deteriorating
Inflammatory state
Favorable
Nutritional resilience
Favorable
Discontinuation risk
15%
Trajectory
Baseline → today → 30-day prediction · hover a day for signals and eventssolid = observed · dashed = predicted
- Day 0 NBL-101 started — Baseline state S17
- Day 59 SC-12 recommended — Supportive Compound SC-12
- Day 60 Patient declined — Not now
What changed?
Trajectory is tracking the baseline prediction.
Primary contributors, last 14 days
- Toxicity-12
- GI instability+8
- Treatment adherence+4
- Inflammatory activity-3
- Nutritional resilience+3
What helped?
- Supportive Compound SC-12Day 59Declined by patient
LIFE OS recommendation
No intervention is indicated right now. The trajectory is stable relative to similar patients. See what worked for similar patients.
Daily trackers
Molecule settingsThe trackers this program marks as important, last 14 days vs the 14 before.
GI burden
Companion12.3/100
improving · -9.7 vs previous 14 d
Toxicity
Blood7.3/100
improving · -1.1 vs previous 14 d
Sleep quality
Wearable65.7/100
improving · +5.2 vs previous 14 d
Energy level
Daily log7.9/10
improving · +0.6 vs previous 14 d
Stress level
Daily log3.4/10
improving · -0.3 vs previous 14 d
Steps
Wearable9,862
improving · +521 vs previous 14 d
Adherence
Companion94.7 %
stable · -2.2 vs previous 14 d
This trajectory is doing well — what to keep, what to watch
Steering view →Heading towards restoration · 93 from the failing basin, 7 from restoration.
Good elements to keep
- Butyrate producers intacthidden · steering +7.5
- Daily walks resumedperturbation · steering +3.3
Main detractors to watch
- Bacteroides fragilis elevatedhidden · steering -7.4
- Poor-sleep weekperturbation · steering -3
- Dietary driftperturbation · steering -2.6
State influencers · digestive
Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.
- Spicy / capsaicin-0.9no signal · 21%
- Dietary fat load-0.8no signal · 20%
- Alcohol+0.7no signal · 17%
- Histamine load-0.6no signal · 15%
- Simple carbohydrates+0.2no signal · 15%
- Insoluble fibre+0.2no signal · 15%
Biological layers
Which pathways look influenced, and by which layer of this person's biology.
Pathways under pressure
- Autonomic recovery ↓25
- WearableResting HR 75 bpm
- Inflammatory signalling ↓20
- MicrobiomeBacteroides fragilis expansion
DNA
Fictional pharmacogenomic panel
- CYP2D6 Intermediate metabolizerExpected exposure
- MTHFR C677TReduced folate turnover
Microbiome
Shannon diversity 4.6 · butyrate capacity 69/100
- Akkermansia muciniphilaNormal
- Faecalibacterium prausnitziiNormal
- Bacteroides fragilisHigh
- Bifidobacterium longumLow
- EnterobacteriaceaeNormal
Wearable, last 14 days
daily evolution fed into the runtime
- HRV
- 44 ms
- Sleep
- 8.1 h
- Steps
- 10,004
- Resting HR
- 71 bpm
Daily log: GI score 12, nutritional resilience 71, adherence 95.
What this patient sees in NostraAI
The content that steers the trajectory: what to eat, what to do, what to take.
What to eat
- Keep meals regular; three to four moderate portions spaced through the day
- Include a cooked vegetable portion with each main meal
- Keep fibre steady; no new sources this week
- Avoid known triggers for now: fried or oily food, dairy, alcohol
What to do
- Log the daily check-in; one line is enough
- Keep the current walking rhythm
- Keep the sleep window steady
- Keep hydration steady: small amounts through the day rather than large volumes at once
What to take
- Take the scheduled dose as agreed with your care team
- No additional supplements this week
- Fictional demo item: continue vitamin D as before
284 biologically similar trajectories
Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.
| Patient | Similarity | Baseline | Intervention | Outcome | Response today |
|---|---|---|---|---|---|
| P-01766 | 41% | S05 | AD-05 | no change | 90 |
| P-01804 | 30% | S19 | AD-05 | improved | 61 |
| P-01541 | 26% | S09 | AD-05 | no change | 43 |
| P-01495 | 48% | S07 | BR-03 | improved | 85 |
| P-01329 | 44% | S08 | BR-03 | improved | 79 |
| P-01677 | 41% | S05 | BR-03 | no change | 86 |
| P-01654 | 53% | S08 | CR-01 | improved | 85 |
| P-01430 | 27% | S05 | CR-01 | improved | 54 |
| P-01479 | 38% | S15 | DT-01 | improved | 84 |
| P-01855 | 35% | S04 | DT-01 | improved | 73 |
| P-01767 | 32% | S14 | DT-01 | no change | 63 |
| P-01724 | 31% | S10 | DT-01 | improved | 63 |